PUTRAJAYA, Oct 25 (Bernama) -- Clinical Research Malaysia (CRM), as an enabler and facilitator to the industry and medical fraternity for the conduct of clinical trials in Malaysia, targets to attract 1,000 industry-sponsored research (ISR) by 2020.
Its chief executive officer, Dr Akhmal Yusof said CRM was also committed to establishing Malaysia as a preferred destination for ISR and to develop clinical research as an economic growth engine.
CRM, wholly owned by the Health Ministry, supports growth in ISR, facilitates the needs and requirements of industry players, and grows a pool of capable investigators, support staff and trial sites.
"CRM's deep understanding of the local clinical research landscape with the international standards of operations and support from the Health Ministry, provide CRM an advantage to deliver research and create high-skilled job opportunities," he said in his opening note at the 2nd CRM Industry Dialogue 2016, here, today.
Some 50 participants, mostly representatives of pharmaceutical companies, contract research organisations and industry players attended the half-day dialogue with the objective of updating the clinical research industry on local laws, guidelines and regulations.
Speakers at the dialogue included representatives of the Medical Device Authority, Malaysian Investment Development Authority (MIDA), Royal Malaysian Customs Department and Malaysian Bioeconomy Development Corporation Sdn Bhd.
The topics discussed included Classification of Medical Device, Incentives in Research and Development, GST Relief on Support Medical Device and Application Process for Notification of Clinical Investigation.
-- BERNAMA
No comments:
Post a Comment